You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Brief cognitive-behavioural therapy reduces hospital readmission but does not reduce overall symptoms of schizophrenia

http://dx.doi.org/10.1136/ebmh.10.2.55

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Turkington D, Kingdon D, Rathod S, et al. Outcomes of an effectiveness trial of cognitive-behavioural intervention by mental health nurses in schizophrenia. Br J Psychiatry 2006;189:36–40.OpenUrlAbstract/FREE Full Text

    Q Is brief cognitive-behavioural therapy effective for people with schizophrenia?

    METHODS

    Embedded ImageDesign:

    Randomised controlled trial.

    Embedded ImageAllocation:

    Concealed.

    Embedded ImageBlinding:

    Single blind (assessors blinded).

    Embedded ImageFollow-up period:

    One year.

    Embedded ImageSetting:

    Six healthcare sites, UK; time period not stated.

    Embedded ImagePatients:

    422 people with schizophrenia (ICD-10). Most participants had ongoing symptoms or were at risk of relapse. Exclusions: currently experiencing schizophrenia relapse, primary diagnosis of alcohol or substance abuse, organic brain disease, or learning disability.

    Embedded ImageIntervention

    Brief cognitive-behavioural therapy (CBT: 6 technique-based sessions over 2–3 months given by trained mental health nurses—including techniques for managing positive and negative symptoms and improving medication compliance) or usual care.

    Embedded ImageOutcomes:

    Primary outcomes: overall symptoms (Comprehensive Psychopathological Rating …

    View Full Text

    Footnotes

    • For correspondence: Professor Douglas Turkington, School of Neurology, Neurosciences and Psychiatry, Royal Victoria Infirmary, Richardson Road, Newcastle upon Tyne NE1 4LP, UK; douglas.turkington{at}ncl.ac.uk

    • Source of funding: Pfizer.